STOCKHOLM – June 20, 2018 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, has made a first on-site installation of a prototype version of INIFYTM Prostate, a sophisticated AI-based decision support tool, with the potential to facilitate and significantly speed up prostate cancer diagnosis based on digitalized H&E stained biopsy samples. The installation was made through the fully integration with the Hospital’s Laboratory Information System at the pathology department at Ospedale Cannizzaro in Catania, Italy.
“We have a fully digital workflow in our lab and we are very excited to start adding image analysis software that helps us further improve the workflow, and we are looking forward to working with ContextVision on this matter,” said Dr. Filippo Fraggetta, chief pathologist at Pathology Unit, Cannizzaro Hospital.
ContextVision prototype for image analysis also includes viewer and annotation tools. The laboratory in Catania will serve as a test center to provide feedback to the project and ensure smooth integration of the product into the clinical workflow.
“We are very pleased to collaborate with Dr. Fraggetta and his team. Thanks to a close dialogue with such an advanced fully digital pathology clinic, with highly-skilled and experienced users, we will be able to specify the product requirements further. The performance of the product not only depends on the quality of the algorithms but on the performance of the product as a whole,” said Anita Tollstadius, CEO at ContextVision.
The prototype was pre-launched recently at the European Congress on Digital Pathology (ECPD) in Helsinki and the algorithm development will continue during the year with the aim to release a first CE-marked product by the end of the year.
“We have proven our capabilities to develop highly specific algorithms through our good results in the highly reputable competition, “The Camelyon Challenge”, and we will continue to develop the algorithms for prostate cancer as well as to fine-tune the workstation though an iterative process, with feedback from Dr. Fraggetta and his team,” said Tollstadius.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, at cell: +46 70 337 30 26 or visit www.contextvision.com
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit https://www.contextvision.com.
About Ospedale Cannizzaro, Catania
The hospital in Catania is a Regional Reference Hospital for emergencies and is home to highly specialized facilities, equipped with advanced and innovative diagnostic and therapeutic technologies. The hospital’s mission is to manage highly complex pathologies, through a multidisciplinary approach. The positioning of the company in the regional and national panorama derives from the high clinical-scientific level achieved over the years by the professionals who work there, from the ability to ensure a technological development consistent with the high specialization of the intervention sectors and the implementation of solutions management that promote the improvement of performance levels and efficiency.
The hospital has a total of 564 beds, of which 502 are inpatient and 62 for day hospital / day service activities, serving the population in Eastern Sicily, equal to 2.6 million inhabitants.